Skip to main content
MedPathMedPath Home
Clinical Trials/EUCTR2005-001008-37-SE
EUCTR2005-001008-37-SE
Active, not recruiting
Not Applicable

Analysis of the antibody level against interferon beta before and after increase of dose in MS therapy - Interferon beta dose and antibody

Sahlgrenska University Hospital0 sites100 target enrollmentMarch 21, 2005
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsMultiple sclerosis
DrugsRebif®

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Multiple sclerosis
Sponsor
Sahlgrenska University Hospital
Enrollment
100
Status
Active, not recruiting
Last Updated
14 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
March 21, 2005
End Date
TBD
Last Updated
14 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
Sahlgrenska University Hospital

Eligibility Criteria

Inclusion Criteria

  • •Multiple sclerosis patients aged 18\-65 years treated by Rebif 22 microgram/dose for more than 1 year.
  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range:
  • •F.1\.2 Adults (18\-64 years) yes
  • •F.1\.2\.1 Number of subjects for this age range
  • •F.1\.3 Elderly (\>\=65 years) no
  • •F.1\.3\.1 Number of subjects for this age range

Exclusion Criteria

  • •Insufficient patient compliance.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
Changes in specific antibody titers and interferon gamma levels after a BNT162b2 vaccine boosterCOVID-19
JPRN-UMIN000048810Fukuoka City Hospital400
Completed
Not Applicable
Changes in specific antibody titers and interferon gamma levels after an Omicron BA.4/BA.5-Adapted Bivalent BoosterCOVID-19
JPRN-UMIN000049273Fukuoka City Hospital150
Completed
Not Applicable
A study of expression levels of the interferon regulated genes in Japanese systemic lupus erythematosus patients with moderate to severe disease activities and healthy adultsSystemic lupus erythematosus
JPRN-UMIN000008987Chugai Pharmaceutical co., ltd.110
Completed
Not Applicable
A study of expression levels of the interferon regulated genes in Japanese systemic lupus erythematosus patients with moderate to severe disease activities and healthy adultsSystemic lupus erythematosus
JPRN-UMIN000009040Chugai Pharmaceutical co., ltd.110
Completed
Not Applicable
A study of expression levels of the interferon regulated genes in Japanese systemic lupus erythematosus patients with moderate to severe disease activities and healthy adults
JPRN-UMIN000008787Chugai Pharmaceutical co., ltd.110